Fitness Trends Amyotrophic Lateral Sclerosis (ALS) Treatment Mark

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market,
By Drug Type, Distribution Channel, Geography - Global
Industry Insights, Trends, Outlook, and Opportunity Analysis,
2018-2026
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron
disease (MND), is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord
that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse
over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around
14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases
per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and
around 15,908 people were diagnosed with ALS in 2013, according to the same study. The
increasing prevalence of ALS is in turn, expected to support growth of the amyotrophic lateral
sclerosis (ALS) treatment market in the near future.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1206
Approval of novel innovative drugs is expected to boost growth in amyotrophic lateral sclerosis
treatment market
In May 2017, The U.S. Food and Drug Administration (FDA) approved Radicava
(edaravone), an innovative drug used in the treatment of amyotrophic lateral sclerosis
(ALS). This was the first drug to be approved after over 20 years since the last FDA-
approved drug for ALS. The approval of this drug would provide an additional option
for patients suffering from this deadly disease. Increasing incidence of ALS is expected to
increase the adoption rate of this drug, in turn, boosting market growth. The drug has
already been approved in Japan and South Korea in 2015.
Report includes chapters which deeply display the following deliverable about industry :
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Objective and
Assumption
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Purview - Report Description,